Senti Biosciences, Inc. (NASDAQ:SNTI) Shares Purchased by ARK Investment Management LLC

ARK Investment Management LLC boosted its holdings in Senti Biosciences, Inc. (NASDAQ:SNTI) by 7.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,969,860 shares of the company’s stock after buying an additional 143,785 shares during the quarter. ARK Investment Management LLC’s holdings in Senti Biosciences were worth $1,300,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. TD Asset Management Inc grew its position in Senti Biosciences by 88.4% during the 3rd quarter. TD Asset Management Inc now owns 241,208 shares of the company’s stock worth $102,000 after purchasing an additional 113,172 shares in the last quarter. Triatomic Management LP grew its position in Senti Biosciences by 42.5% during the 2nd quarter. Triatomic Management LP now owns 300,533 shares of the company’s stock worth $188,000 after purchasing an additional 89,650 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Senti Biosciences by 11.9% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 4,015,483 shares of the company’s stock worth $8,714,000 after purchasing an additional 425,898 shares in the last quarter. Geode Capital Management LLC grew its position in Senti Biosciences by 19.7% during the 4th quarter. Geode Capital Management LLC now owns 200,187 shares of the company’s stock worth $282,000 after purchasing an additional 32,912 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in Senti Biosciences during the 2nd quarter worth approximately $71,000. Institutional investors and hedge funds own 25.73% of the company’s stock.

Senti Biosciences Stock Performance

Senti Biosciences stock opened at $0.39 on Thursday. The company’s fifty day simple moving average is $0.42 and its 200-day simple moving average is $0.43. Senti Biosciences, Inc. has a 12 month low of $0.27 and a 12 month high of $1.26.

Senti Biosciences (NASDAQ:SNTI) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter. Senti Biosciences had a negative net margin of 2,692.82% and a negative return on equity of 74.59%. On average, analysts forecast that Senti Biosciences, Inc. will post -1 EPS for the current year.

Senti Biosciences Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.